BR112016001544A8 - composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório - Google Patents
composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório Download PDFInfo
- Publication number
- BR112016001544A8 BR112016001544A8 BR112016001544A BR112016001544A BR112016001544A8 BR 112016001544 A8 BR112016001544 A8 BR 112016001544A8 BR 112016001544 A BR112016001544 A BR 112016001544A BR 112016001544 A BR112016001544 A BR 112016001544A BR 112016001544 A8 BR112016001544 A8 BR 112016001544A8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- agent
- intraocular administration
- antibacterial agent
- inflammatory agent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 title abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 abstract 1
- 229960003702 moxifloxacin Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361958170P | 2013-07-22 | 2013-07-22 | |
| PCT/US2014/032026 WO2015012899A1 (en) | 2013-07-22 | 2014-03-27 | Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016001544A2 BR112016001544A2 (pt) | 2017-07-25 |
| BR112016001544A8 true BR112016001544A8 (pt) | 2021-08-03 |
Family
ID=50640013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016001544A BR112016001544A8 (pt) | 2013-07-22 | 2014-03-27 | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150024996A1 (https=) |
| EP (1) | EP3024475B8 (https=) |
| JP (5) | JP2016525544A (https=) |
| KR (1) | KR20160033213A (https=) |
| AU (1) | AU2014293665B2 (https=) |
| BR (1) | BR112016001544A8 (https=) |
| CA (1) | CA2919081C (https=) |
| IL (1) | IL243750A0 (https=) |
| MX (1) | MX383077B (https=) |
| WO (1) | WO2015012899A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| MX383077B (es) * | 2013-07-22 | 2025-03-13 | Novel Drug Solutions Llc | Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio. |
| JP6682898B2 (ja) * | 2016-02-17 | 2020-04-15 | 富士通株式会社 | 基地局、無線通信システムおよび基地局の処理方法 |
| CA3023243C (en) * | 2016-05-06 | 2020-01-21 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions and methods for fabricating thereof |
| DK3541442T3 (da) | 2016-11-16 | 2022-03-14 | Persica Pharmaceuticals Ltd | Antibiotiske formuleringer mod lændesmerter |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| US11523987B2 (en) | 2020-08-26 | 2022-12-13 | Somerset Therapeutics, Llc | Trimcinolone and moxifloxacin methods |
| US11510930B2 (en) | 2020-08-26 | 2022-11-29 | Somerset Therapeutics, Llc | Gatifloxacin, prednisolone, and bromfenac compositions and methods |
| US12102632B2 (en) | 2020-08-26 | 2024-10-01 | Somerset Therapeutics, Llc | Quinolone dispersions |
| US11382910B2 (en) | 2020-08-26 | 2022-07-12 | Somerset Therapeutics, Llc. | Loteprednol and moxifloxacin compositions and methods |
| EP4260844B1 (en) | 2022-04-11 | 2026-03-18 | Liegner, Jeffery T. | Ophthalmological compositions comprising poloxamer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1192368A (ja) * | 1997-07-23 | 1999-04-06 | Ono Pharmaceut Co Ltd | ベンゾピラン誘導体を主成分とする水性液剤 |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| JP2003176228A (ja) * | 2001-12-11 | 2003-06-24 | Rohto Pharmaceut Co Ltd | 液 剤 |
| US20070049552A1 (en) * | 2003-04-14 | 2007-03-01 | Babu Manoj M | Fluoroquinolone formulations and methods of making and using the same |
| BRPI0609227A2 (pt) * | 2005-05-10 | 2010-03-09 | Alcon Inc | composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos |
| US20080262415A1 (en) * | 2005-07-18 | 2008-10-23 | Peyman Gholam A | Enhanced wound healing |
| EP2370054B1 (en) * | 2008-12-11 | 2015-10-07 | Massachusetts Institute of Technology | Contact lens drug delivery device |
| JP2013508381A (ja) * | 2009-10-21 | 2013-03-07 | オトノミ―，インク． | ポロクサマーを包含する製剤のゲル化温度の調節 |
| EP2490722A4 (en) * | 2009-10-21 | 2014-03-05 | Otonomy Inc | MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS |
| US20140127269A1 (en) * | 2012-02-13 | 2014-05-08 | The Schepens Eye Research Institute, Inc. | Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof |
| MX383077B (es) * | 2013-07-22 | 2025-03-13 | Novel Drug Solutions Llc | Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio. |
-
2014
- 2014-03-27 MX MX2016000964A patent/MX383077B/es unknown
- 2014-03-27 WO PCT/US2014/032026 patent/WO2015012899A1/en not_active Ceased
- 2014-03-27 EP EP14721688.1A patent/EP3024475B8/en active Active
- 2014-03-27 US US14/227,819 patent/US20150024996A1/en not_active Abandoned
- 2014-03-27 KR KR1020167004393A patent/KR20160033213A/ko not_active Ceased
- 2014-03-27 JP JP2016529754A patent/JP2016525544A/ja active Pending
- 2014-03-27 BR BR112016001544A patent/BR112016001544A8/pt not_active Application Discontinuation
- 2014-03-27 CA CA2919081A patent/CA2919081C/en active Active
- 2014-03-27 AU AU2014293665A patent/AU2014293665B2/en active Active
-
2016
- 2016-01-24 IL IL243750A patent/IL243750A0/en active IP Right Grant
-
2019
- 2019-06-11 JP JP2019108368A patent/JP7232128B2/ja active Active
-
2021
- 2021-05-18 JP JP2021083925A patent/JP2021121608A/ja active Pending
-
2022
- 2022-09-30 JP JP2022157885A patent/JP7362870B2/ja active Active
-
2023
- 2023-10-04 JP JP2023172708A patent/JP2024001149A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015012899A1 (en) | 2015-01-29 |
| MX383077B (es) | 2025-03-13 |
| JP2019167376A (ja) | 2019-10-03 |
| EP3024475A1 (en) | 2016-06-01 |
| JP7362870B2 (ja) | 2023-10-17 |
| AU2014293665A1 (en) | 2016-02-11 |
| AU2014293665B2 (en) | 2017-06-01 |
| CA2919081A1 (en) | 2015-01-29 |
| IL243750A0 (en) | 2016-04-21 |
| US20150024996A1 (en) | 2015-01-22 |
| EP3024475B8 (en) | 2020-11-18 |
| NZ716208A (en) | 2020-12-18 |
| JP7232128B2 (ja) | 2023-03-02 |
| CA2919081C (en) | 2021-11-16 |
| JP2022185059A (ja) | 2022-12-13 |
| HK1223824A1 (zh) | 2017-08-11 |
| JP2016525544A (ja) | 2016-08-25 |
| JP2024001149A (ja) | 2024-01-09 |
| MX2016000964A (es) | 2016-08-03 |
| EP3024475B1 (en) | 2020-09-30 |
| BR112016001544A2 (pt) | 2017-07-25 |
| JP2021121608A (ja) | 2021-08-26 |
| KR20160033213A (ko) | 2016-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| UA124347C2 (uk) | Циклічна динуклеотидна сполука | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX394961B (es) | Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6 | |
| BR112016001678A2 (pt) | Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| MX382255B (es) | Composiciones de suministro de farmaco implantables y metodos de uso de las mismas. | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| BR112015017246A8 (pt) | composição farmacêutica aquosa, seu uso e seringa | |
| BR112016007328A2 (pt) | composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas | |
| BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
| CA2929865C (en) | Sprayable topical carrier and composition comprising phosphatidylcholine | |
| MX2019001633A (es) | Proteina derivada de la seda para el tratamiento de la inflamacion. | |
| BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112018007068A2 (pt) | derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta | |
| NZ735777A (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| BR112017026904A2 (pt) | formulações farmacêuticas injetáveis de lefamulina | |
| TR201310724A2 (tr) | Linagliptinin farmasotik formulasyonları. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B25D | Requested change of name of applicant approved |
Owner name: HARROW HEALTH, INC. (US) |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25C | Requirement related to requested transfer of rights |
Owner name: HARROW HEALTH, INC. (US) Free format text: A FIM DE ATENDER A(S) TRANSFERENCIA(S), REQUERIDA(S) ATRAVES DA PETICAO NO 870200049634DE 20/04/2020, E NECESSARIO:1. QUE O DOCUMENTO QUE COMPROVA A TRANSFERENCIA ESTEJA ACOMPANHADO DA LEGALIZACAOCONSULAR OU DA APOSTILA DE HAIA. 2. APRESENTAR GRU REFERENTE AO CUMPRIMENTO DA PRESENTE EXIGENCIA. |
|
| B25B | Requested transfer of rights rejected |
Owner name: HARROW HEALTH, INC. (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: NOVEL DRUG SOLUTIONS LLC (US) ; EYE CARE NORTHWEST, PA (US) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |